Asia Pacific Human Insulin Market Size, Share & COVID-19 Impact Analysis, By Type (Analog Insulin and Traditional Insulin), By Diabetes Type (Diabetes 1 and Diabetes 2), By Distribution Channel (Hospital Pharmacy and Retail & Online Pharmacy), and Regional Forecast, 2023-2030

The Asia Pacific region holds a significant share in the global human insulin market. Asia Pacific human insulin market size is projected to grow at a CAGR of 2.4% during the estimated period. The global human insulin market is projected to expand from USD 18.7 billion in 2022 to USD 21.04 billion by 2030.

The rising population suffering from diabetes has led to a high demand for human insulin therapy in the Asia Pacific region. According to an article published by the Australian Institute of Health and Welfare in February 2023, an estimated 1.3 million Australian population suffered from diabetes in 2020. As per similar statistics, the National (insulin-treated) Diabetes Register (NDR) stated that around 30,800 people used insulin to treat their diabetes in 2020.

Our report on the Asia Pacific market covers the following countries/regions – China, India, Australia, Japan, Southeast Asia, and the Rest of Asia Pacific.

LATEST TRENDS

Entrance of Local Players with New Products to Promote Market Growth

The rising prevalence of diabetes among the population creates a demand for new insulin products. Thus, several key players are now focusing on entering the market and offering an extensive product portfolio with a vast regional distribution network. Therefore, the rising adoption of these products by the Asia Pacific for diabetes therapy further aids Asia Pacific human insulin market growth.

• In February 2022, Eris Lifesciences Ltd, an Indian-based chronic therapy-focused company, announced a vision for acquiring a 10.0% market share in the India human insulin market by launching Xsulin, a human insulin solution.          

DRIVING FACTORS

Rising Market Penetration of Key Players across Emerging Nations to Boost Market Expansion

The adoption of insulin products is high among the population in the Asia Pacific countries owing to increasing prevalence of diabetes among adults and children. Thus, due to high demand, several major players are now focusing on the launch and market expansion of their product portfolio across emerging countries. Moreover, rising approval of insulin delivery products by regulatory organizations in the region will further augment regional growth.

For instance, in June 2021, Novo Nordisk A/S obtained Japanese regulatory approval for NovoPen 6 and NovoPen Echo Plus human insulin pens.

RESTRAINING FACTORS

Surge In Undiagnosed Diabetic Patients Across the Region to Restrain Market Growth

The number of people with type 1 diabetes in developing economies of the Asia pacific region is high. However, the lack of awareness and low volume of diabetes testing among the population led to a large number of undiagnosed patients, further declining the adoption of insulin therapy. Thus, these factors led to limited sales of human insulin products, restraining the market growth.

According to IDF Atlas 2021 volume, almost 90.0% of population with undiagnosed diabetes were living in low and middle-income countries. As per similar statistics, more than half of the diabetic population in the Western Pacific remains undiagnosed every year.

KEY INDUSTRY PLAYERS

Novo Nordisk A/S and Sanofi held the largest part in the Asia Pacific human insulin market share in terms of revenue in 2022. Other players operating in the market are Eris Lifesciences Ltd., and Gan & Lee Pharmaceuticals Co. Ltd., and others.

The rising partnerships and joint ventures among the leading players and rising R&D centers across the region will boost the company’s share in the market. Furthermore, increasing collaborations among key players to boost human insulin production in the region's developing economies will enhance market growth

KEY INDUSTRY DEVELOPMENTS

• August 2022: The China Medical System Holdings Limited Group, through its subsidiary Rxilient Medical Pte. Ltd entered into a collaboration and supply agreement with Hefei Tianmai Biotechnology Development Co., Ltd, a biopharmaceutical company, for the second-generation insulin series products and the third-generation insulin analogue glargine insulin injection.


• December 2021: Taiwanese digital health startup, Health2Sync, and Sanofi, a French multinational pharmaceutical firm, entered an extended partnership for marketing a new solution for insulin management. The partnership focuses on bringing clinical efficacy with real-world evidence of the connected eco-system and insulin management solution.


• December 2021: Eris Lifesciences Ltd entered a joint venture with MJ Biopharm Pvt Ltd. to enter the marketing and distribution segment of human and analogue insulin products.

LIST OF KEY COMPANIES PROFILED:

• Novo Nordisk A/S (Denmark)


• Eli Lilly and Company (U.S.)


• Sanofi (France)


• WOCKHARDT (India)


• Biocon (India)


• Lupin (India)


• Eris Lifesciences Ltd (India)


• Tonghua Dongbao Pharmaceutical Co., Ltd. (China)


• Gan & Lee Pharmaceuticals Co. Ltd (Germany)


• The United Laboratories International Holdings Limited (China)

REPORT COVERAGE

The Asia Pacific human insulin market report provides a detailed market analysis. It focuses on key aspects such as the launch of new products, technological advancements, and the prevalence of diabetes. Besides this, the report offers insights into the market trends and highlights key industry developments such as mergers, partnerships, and acquisitions and the impact of COVID-19 on the market. In addition to the above mentioned factors, the report encompasses several factors that have contributed to the market growth over recent years.

Report Scope & Segmentation